AVLN
Avalyn Pharma Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-37/100
Last price
25.88
▲ 0.45 (1.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.30
Prev close
25.43
Day high
26.31
Day low
25.26
Volume
82.51K
Market cap
$1.15B
P/E (TTM)
—
52W range
24.15 – 40.17
Day trading desk
Gap from prior close
-0.51%
Prior close 25.43
VWAP
25.82
+0.22% from price
Relative volume
0.34×
Quiet session
Session range
4.18%
25.25 – 26.31
Position in range
59%
Mid range
ATR (14D)
2.06
7.98% of price
Prior day high
27.22
PDH
Prior day low
25.06
PDL
Bid / ask spread
—
Quote not published
Session volume
80.84K
Avg 238.20K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.18%
-11.1%
1M
-31.22%
-32.7%
3M
-10.53%
-14.0%
6M
—
-15.0%
YTD
-12.26%
-26.3%
1Y
—
-15.8%
3Y
—
-81.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AVLN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 1, 26 | NOVO HOLDINGS A/S Beneficial Owner of more than 10% of a Class of Security |
BUY | 555.55K | $16.58M | Direct |
| May 1, 26 | NOVO HOLDINGS A/S Beneficial Owner of more than 10% of a Class of Security |
— | 3.33M | — | Direct |
| May 1, 26 | CARROLL JILL Director |
BUY | 277.78K | $8.29M | Indirect |
| May 1, 26 | CARROLL JILL Director |
— | 1.91M | — | Indirect |
| May 1, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 555.55K | $16.58M | Indirect |
| May 1, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
— | 2.75M | — | Indirect |
| May 1, 26 | FMR LLC Beneficial Owner of more than 10% of a Class of Security |
— | 2.28M | — | Indirect |
| May 1, 26 | WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II Beneficial Owner of more than 10% of a Class of Security |
— | 1.28M | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARROLL JILL |
Director | — | Purchase |
FMR LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
NOVO HOLDINGS A/S |
Beneficial Owner of more than 10% of a Class of Security | 3.88M | Purchase |
SR ONE CAPITAL MANAGEMENT, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II |
Beneficial Owner of more than 10% of a Class of Security | 1.28M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.15B
Enterprise value$792.07M
Revenue (TTM)—
Gross profit—
EBITDA$-109.80M
Net income$-103.31M
EPS (TTM)$-2.47
Free cash flow—
Total cash$352.42M
Total debt$17.11M
Book value / share$8.99
Shares outstanding44.33M
Float27.41M
Short % of float4.72%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.62
PEG ratio—
Price / sales—
Price / book2.88
EV / revenue—
EV / EBITDA-7.21
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity4.30
Current ratio33.12
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $76.61M | $45.76M | +67.4% |
| Selling, general & admin | $14.68M | $11.36M | +29.2% |
| Total operating expense | $91.29M | $57.12M | +59.8% |
| Operating income | -$91.29M | -$57.12M | -59.8% |
| Net interest income | $6.18M | $7.44M | -17.0% |
| Pre-tax income | -$85.20M | -$49.74M | -71.3% |
| Net income | -$85.20M | -$49.74M | -71.3% |
| Net income to common | -$85.20M | -$49.74M | -71.3% |
| Basic EPS | -2.04 | -1.19 | -71.3% |
| Diluted EPS | -2.04 | -1.19 | -71.3% |
| EBIT | -$91.29M | -$57.12M | -59.8% |
| EBITDA | -$91.25M | -$57.09M | -59.8% |
| Basic shares | 41.81M | 41.81M | 0.0% |
| Diluted shares | 41.81M | 41.81M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $52.31M | $23.95M | +118.4% |
| Cash & short-term investments | $138.36M | $110.63M | +25.1% |
| Total current assets | $143.56M | $114.39M | +25.5% |
| Property, plant & equipment | $2.32M | $94.00K | +2,370.2% |
| Total assets | $148.88M | $124.52M | +19.6% |
| Total current liabilities | $14.09M | $8.74M | +61.2% |
| Total debt | $1.67M | $0 | — |
| Total liabilities | $387.54M | $299.04M | +29.6% |
| Retained earnings | -$265.36M | -$180.16M | -47.3% |
| Shareholder equity | -$238.66M | -$174.52M | -36.7% |
| Working capital | $129.47M | $105.64M | +22.6% |
| Net tangible assets | -$238.66M | -$174.52M | -36.7% |
| Shares issued | 41.81M | 41.81M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$85.20M | -$49.74M | -71.3% |
| Depreciation & amortisation | $42.00K | $29.00K | +44.8% |
| Stock-based compensation | $3.27M | $2.47M | +32.5% |
| Change in working capital | $2.61M | $1.36M | +92.0% |
| Operating cash flow | -$81.48M | -$48.37M | -68.5% |
| Capital expenditure | -$344.00K | -$95.00K | -262.1% |
| Investing cash flow | $10.06M | -$91.47M | +111.0% |
| Financing cash flow | $99.79M | $89.00K | +112,020.2% |
| Free cash flow | -$81.83M | -$48.46M | -68.8% |
| End cash position | $52.31M | $23.95M | +118.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $24.73M | $22.89M | $17.88M | $15.32M | +8.0% |
| Selling, general & admin | $6.56M | $5.02M | $3.90M | $3.40M | +30.7% |
| Total operating expense | $31.29M | $27.91M | $21.78M | $18.72M | +12.1% |
| Operating income | -$31.29M | -$27.91M | -$21.78M | -$18.72M | -12.1% |
| Net interest income | $2.42M | $1.03M | $1.63M | $1.25M | +136.0% |
| Pre-tax income | -$28.93M | -$26.87M | -$20.19M | -$17.50M | -7.7% |
| Net income | -$28.93M | -$26.87M | -$20.19M | -$17.50M | -7.7% |
| Net income to common | -$28.93M | -$26.87M | -$20.19M | -$17.50M | -7.7% |
| Basic EPS | -0.65 | -0.64 | -0.48 | -0.42 | -1.6% |
| Diluted EPS | -0.65 | -0.64 | -0.48 | -0.42 | -1.6% |
| EBIT | -$28.66M | -$26.77M | -$20.19M | -$17.50M | -7.1% |
| EBITDA | -$28.55M | -$26.71M | -$20.18M | -$17.49M | -6.9% |
| Basic shares | 44.33M | 41.81M | 41.81M | 41.81M | +6.0% |
| Diluted shares | 44.33M | 41.81M | 41.81M | 41.81M | +6.0% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $264.20M | $92.31M | +186.2% |
| Cash & short-term investments | $352.43M | $123.13M | +186.2% |
| Total current assets | $357.99M | $129.99M | +175.4% |
| Property, plant & equipment | $3.35M | $2.68M | +25.0% |
| Total assets | $425.45M | $135.66M | +213.6% |
| Total current liabilities | $10.81M | $11.79M | -8.3% |
| Long-term debt | $14.80M | $14.81M | -0.0% |
| Total debt | $17.11M | $16.41M | +4.3% |
| Total liabilities | $27.10M | $399.91M | -93.2% |
| Retained earnings | -$321.17M | -$292.23M | -9.9% |
| Shareholder equity | $398.35M | -$264.25M | +250.7% |
| Working capital | $347.18M | $118.20M | +193.7% |
| Net tangible assets | $398.35M | -$264.25M | +250.7% |
| Shares issued | 44.33M | 41.81M | +6.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$28.93M | -$26.87M | -$20.19M | -$17.50M | -7.7% |
| Depreciation & amortisation | $110.00K | $63.00K | $9.00K | $10.00K | +74.6% |
| Stock-based compensation | $2.79M | $1.19M | $1.13M | $543.00K | +133.9% |
| Change in working capital | $10.00K | -$4.16M | -$1.17M | -$1.77M | +100.2% |
| Operating cash flow | -$26.08M | -$29.89M | -$20.70M | -$19.27M | +12.8% |
| Capital expenditure | -$269.00K | -$318.00K | — | -$8.00K | +15.4% |
| Investing cash flow | -$118.71M | $55.02M | -$36.69M | $24.12M | -315.7% |
| Financing cash flow | $316.67M | $14.86M | $89.88M | $0 | +2,030.8% |
| Free cash flow | -$26.34M | -$30.21M | -$20.70M | -$19.28M | +12.8% |
| End cash position | $264.20M | $92.31M | $61.30M | $28.80M | +186.2% |
Options analytics
Put / call volume
0.45
Call-heavy session
Put / call open interest
1.76
Positioning, not flow
Max pain
35.00
+35.3% from spot
ATM implied vol
66.2%
Nearest strike to spot
Skew (10% OTM)
+42.2%
Puts bid over calls
Call volume
22
Contracts, this expiry
Put volume
10
Contracts, this expiry
Heaviest call OI
35.00
14 contracts
Heaviest put OI
30.00
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.57 | -0.98 | -73.5% |
| Mar 2026 | -0.82 | -21.83 | -2,578.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.79 | 1 | $0 | — |
| Next quarter | -0.83 | 3 | $0 | — |
| Current year | -1.94 | 1 | $0 | — |
| Next year | -1.90 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$61.80
High target$80.00
Low target$52.00
Implied upside138.84%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy2 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions103.99%
Institutions holding135
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
27.44
-5.71% from price
SMA 20
30.27
-14.51% from price
SMA 50
33.20
-22.07% from price
SMA 100
30.92
-16.33% from price
SMA 200
—
—
EMA 12
28.18
-8.20% from price
EMA 26
30.37
-14.80% from price
EMA 50
31.39
-17.57% from price
RSI (14)
32.6
Neutral
MACD (12,26,9)
-2.18
Hist -0.43
ATR (14)
2.06
7.98% of price
Realised vol 30D
55.2%
Annualised
Bollinger upper
36.55
20, 2σ
Bollinger lower
23.98
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.09
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
55.2%
Annualised
Market vol 1Y
12.1%
SPY, annualised
Max drawdown 1Y
-35.2%
Peak to trough
Max drawdown 5Y
-35.2%
Peak to trough
ATR 14
2.06
7.98% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.09M
Prior 2.07M
Change vs prior
+1.0%
Shorts adding
% of float
4.72%
Normal
% of shares out
4.72%
Against total outstanding
Days to cover
10.7
Crowded exit
Float
27.41M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Raymond James | INITIATED | — | Outperform |
| Aug 13, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 26, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| May 26, 26 | Guggenheim | INITIATED | — | Buy |
| May 26, 26 | Morgan Stanley | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-16
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-17
Periodic Financial Reports
10-Q · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-05-01
Offering Registrations
S-8 · 2026-04-30
Offering Registrations
S-1/A · 2026-04-29
Headlines
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
Simply Wall St. · 14d ago
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
GlobeNewswire · 16d ago
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
GlobeNewswire · 21d ago
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · 29d ago
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
GlobeNewswire · 29d ago
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
GlobeNewswire · 44d ago
Avalyn Pharma's Q2 Net Loss Widens
MT Newswires · 56d ago
Avalyn: Q2 Earnings Snapshot
Associated Press · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.